Humacyte, Inc.

Informe acción NasdaqGS:HUMA

Capitalización de mercado: US$246.4m

Humacyte Dirección

Dirección controles de criterios 1/4

El CEO de Humacyte es Laura Niklason , nombrado en Jan 2004, tiene una permanencia de 22.33 años. compensación anual total es $5.23M, compuesta por 12.1% salario y 87.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $270.67K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 4.8 años, respectivamente.

Información clave

Laura Niklason

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO12.10%
Permanencia del CEO22.3yrs
Participación del CEO0.1%
Permanencia media de la dirección1.3yrs
Promedio de permanencia en la Junta Directiva4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Feb 09

Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist

Summary Humacyte, Inc. remains rated Hold despite a DoD funding catalyst revealed today, as commercial traction for Symvess is not yet proven. Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Read the full article on Seeking Alpha
Artículo de análisis • Sep 19

Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis • May 21

Is Humacyte (NASDAQ:HUMA) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 24

Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)

Summary Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious, with high operating expenses and a cash runway extending only into late 2025, raising concerns about future dilution. Given these challenges, I downgrade HUMA to "Sell," as achieving a return on investment for Symvess seems unlikely without significant financial strain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning

Summary Humacyte, Inc. arrived on the Nasdaq in 2021 via a SPAC deal and reappeared on my radar after the Symvess approval in vascular trauma repair. Platform enabling off-the-shelf bioengineered tissues could transform the field of regenerative medicine. There's a large addressable market across 3 lead indications alone (trauma, dialysis & PAD) + significant optionality for more complex projects (i.e., biovascular pancreas in diabetes). Key concerns include slow launch out of the gate, continued cash burn & dilution, competition, and manufacturing capacity. My Action Plan: I remain on the sidelines for HUMA stock and will continue to monitor launch metrics as well as pipeline progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 23

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Summary Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its market potential is limited, and adoption is expected to be slow and costly. Phase 3 trial data for ATEVs in hemodialysis patients showed higher thrombosis and infection rates, raising concerns about its safety and efficacy. Humacyte's financial situation remains precarious, with high operating expenses and potential ongoing dilution, leading to a downgrade on HUMA stock from "buy" to "hold". Read the full article on Seeking Alpha
Seeking Alpha • Dec 14

Humacyte: FDA Waiting Game Bleeding Company Dry

Summary Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong clinical data, the FDA's postponement of the ATEV approval has left Humacyte in a precarious financial position, forcing it to raise ~$45m since August. The lack of a clear FDA timeline creates significant risk for investors, leading to a downgrade from "buy" to "hold" due to potential further delays. The market opportunity for ATEVs remains uncertain, questioning whether Humacyte stock can achieve significant upside even if FDA approval is granted. Read the full article on Seeking Alpha
Seeking Alpha • Sep 24

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Summary Humacyte’s acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma. Risks include potential FDA rejection, financial distress, and management's recent share sales, which warrant cautious investment consideration. Read the full article on Seeking Alpha
Artículo de análisis • Aug 16

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 17

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Summary Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a potentially superior option to traditional treatments. Financially, Humacyte holds sufficient short-term assets but faces significant long-term liabilities and a potential cash crunch within a year. I recommend buying HUMA as a speculative, high-risk/high-reward addition to a diversified investment portfolio. Read the full article on Seeking Alpha
Artículo de análisis • Jun 05

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Key Insights Humacyte's Annual General Meeting to take place on 11th of June Total pay for CEO Laura Niklason includes...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Laura Niklason en comparación con los beneficios de Humacyte?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$95m

Dec 31 2025US$5mUS$634k

-US$41m

Sep 30 2025n/an/a

-US$39m

Jun 30 2025n/an/a

-US$61m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$905kUS$612k

-US$149m

Sep 30 2024n/an/a

-US$153m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$106m

Dec 31 2023US$3mUS$604k

-US$111m

Sep 30 2023n/an/a

-US$89m

Jun 30 2023n/an/a

-US$89m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$2mUS$500k

-US$12m

Sep 30 2022n/an/a

US$34m

Jun 30 2022n/an/a

US$28m

Mar 31 2022n/an/a

-US$26m

Dec 31 2021US$11mUS$500k

-US$26m

Sep 30 2021n/an/a

-US$85m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$69m

Dec 31 2020US$619kUS$75k

-US$67m

Compensación vs. Mercado: La compensación total de Laura($USD5.23M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.66M).

Compensación vs. Ingresos: La compensación de Laura ha aumentado mientras la empresa no es rentable.

CEO

Laura Niklason (62 yo)

22.3yrs
Permanencia
US$5,234,908
Compensación

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Laura Niklason
Founder22.3yrsUS$5.23m0.11%
$ 270.7k
Dale Sander
CFO, Chief Corporate Development Officer & Treasurer5.5yrsUS$2.13m0.019%
$ 47.3k
Shamik Parikh
Chief Medical Officer4.1yrsUS$2.10m0.0034%
$ 8.3k
Sabrina Osborne
Chief People Officerno datasin datossin datos
Lisa Molyneux
Executive Vice President of Enterprise Planning & Analysis1.3yrssin datossin datos
Heather Connelly
Executive Vice President Regulatory Affairs & Quality1.3yrssin datossin datos
Rick McElheny
Senior Vice President of Business Developmentless than a yearsin datossin datos
Jim Mercadante
Chief Commercial Officerless than a yearsin datossin datos
Todd Rasmussen
Chief Surgical Officerno datasin datossin datos
1.3yrs
Permanencia media
62yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de HUMA no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Laura Niklason
Founder22.3yrsUS$5.23m0.11%
$ 270.7k
Max Wallace
Independent Director20.9yrsUS$207.80k0.029%
$ 71.7k
Brady Dougan
Director21.3yrsUS$202.80k0%
$ 0
Susan Windham-Bannister
Independent Director4.8yrsUS$207.80k0%
$ 0
Todd Pope
Independent Directorno dataUS$207.80k0%
$ 0
Kathleen Sebelius
Independent Chairman of the Board10.7yrsUS$227.80k0.067%
$ 164.3k
Michael Constantino
Independent Director4.8yrsUS$210.30k0.020%
$ 48.8k
Diane Seimetz
Independent Director3.9yrsUS$202.80k0%
$ 0
Emery Brown
Independent Director4.8yrsUS$202.80k0%
$ 0
Charles Green
Independent Director3.7yrsUS$202.80k0.0038%
$ 9.3k
John Bamforth
Independent Director1.9yrsUS$202.80k0%
$ 0
Keith Jones
Independent Director1.9yrsUS$202.80k0%
$ 0
4.8yrs
Permanencia media
65.5yo
Promedio de edad

Junta con experiencia: La junta directiva de HUMA se considera experimentada (4.8 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/27 02:47
Precio de las acciones al final del día2026/05/27 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Humacyte, Inc. está cubierta por 9 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Matthew MiksicBarclays
Bruce JacksonBenchmark Company
Michael GormanBTIG